| Muscular Dystrophy, Duchenne
Viltepso vs Exondys 51
Side-by-side clinical, coverage, and cost comparison for muscular dystrophy, duchenne.Deep comparison between: Viltepso vs Exondys 51 with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsExondys 51 has a higher rate of injection site reactions vs Viltepso based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Exondys 51 but not Viltepso, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Viltepso
Exondys 51
At A Glance
IV infusion
Once weekly
Antisense oligonucleotide (PMO)
IV infusion
Once weekly
Antisense oligonucleotide (exon 51 skipper)
Indications
- Muscular Dystrophy, Duchenne
- Muscular Dystrophy, Duchenne
Dosing
Muscular Dystrophy, Duchenne 80 mg/kg once weekly as a 60-minute IV infusion; serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before starting.
Muscular Dystrophy, Duchenne 30 mg/kg once weekly as a 35 to 60 minute IV infusion via an in-line 0.2 micron filter.
Contraindications
—
—
Adverse Reactions
Most common (>=15%) Upper respiratory tract infection, injection site reaction, cough, pyrexia
Common (>=10%) Contusion, arthralgia, diarrhea, vomiting, abdominal pain, ejection fraction decreased, urticaria
Most common (>=35%) balance disorder, vomiting
Postmarketing bronchospasm, cyanosis of the lips, malaise, pyrexia, flushing, protein urine present, dehydration
Pharmacology
Viltolarsen is an antisense oligonucleotide (phosphorodiamidate morpholino oligomer subclass) that binds to exon 53 of dystrophin pre-mRNA, causing exon 53 skipping during mRNA processing and enabling production of an internally truncated dystrophin protein in patients with DMD gene mutations amenable to exon 53 skipping.
Eteplirsen is an antisense phosphorodiamidate morpholino oligomer that binds to exon 51 of dystrophin pre-mRNA, causing exon skipping during mRNA processing to allow production of an internally truncated dystrophin protein in patients with DMD mutations amenable to exon 51 skipping.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Viltepso
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Exondys 51
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
UnitedHealthcare
Viltepso
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Exondys 51
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Viltepso
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Exondys 51
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Duchenne Muscular Dystrophy
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Duchenne Muscular Dystrophy
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ViltepsoView full Viltepso profile
Exondys 51View full Exondys 51 profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.